Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India  by Ganapule, Abhijeet et al.
Table
Patient, disease, and treatment related characteristics (N¼892)
Variables Results
Recipient median age (range), years 53 (19-76)
Recipient gender (%) F ¼ 43%
M ¼ 57%
Donor/recipient gender (%)
F/M 27%
F/F 21%
M/M,F 52%
Donor source (%)
MRD 32%
MUD 43%
MMD 16%
Cord blood 7%
Cell source (%)
PBSC 92%
BM 1%
Cord blood 7%
Diagnoses (%)
AML/MDS 47%
Lymphomas 13%
ALL 14%
Others 26%
Preparative regimen (%)
FLU-BU* 72%
Others 30%
GVHD prophylaxis (%)
Non-sirolimus (MTX/MMF based) 62%
Sirolimus-based 37%
Recipient/Donor CMV serologic status
+/+ 22%
+/- 29%
-/+,- 49%
*includes pharmacokinetically targeted IV busulfan with a median daily
AUC ranging from 3500 to 9000 mmolesmin/L
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S298Results: The median age was 53 (19-76) years old. The
most common myeloablative preparative regimens con-
sisted of ﬂudarabine and pharmacokinetically targeted IV
busulfan (FLU-BU with AUC of 3500-9000) in 94% of
cases. The most common reduced intensity regimen used
was ﬂudarabine and melphalan (52%). Baseline charac-
teristics are described in the table. The overall incidence
of VTE was 6.7% for the entire cohort: 7.2% and 6.4% in
the sirolimus and non-sirolimus groups, respectively,
with odds ratio (OR) ¼ 1.14 (95% CI 0. 67-1.95; p¼0.63).
Of the VTE incidence, catheter related VTE were 37% and
36% for the sirolimus and non-sirolimus groups, respec-
tively. Median onset of VTE was 155 and 233 days with
sirolimus and non-sirolimus, respectively. In multivariate
analysis the risk of VTE increased with every 10-year
increment of recipient age with OR ¼ 1.29 (95% CI 1.03-
1.61; p¼0.026).
Conclusion: The use of sirolimus-based regimen did not
increase the incidence of VTE in allo-HCT recipient. Every 10-
year increment in agewas associated with 29% increased risk
of VTE.427
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An allogeneic SCT (alloSCT) with a reduced intensity condi-
tioning regimen (RIC) in ﬁrst remission (CR1) is an attractive
option to fulﬁll the requirements of relatively low cost
without compromising efﬁcacy. The need for consolidation
chemotherapy prior to offering a RIC alloSCT for AML CR1
remains controversial. To evaluate these aspects we under-
took a retrospective analysis of patients with AML CR1 who
received a RIC alloSCT from multiple centers in India.
Data from 8 centers in India was collected between 2005
and 2013. A total of 138 patients fulﬁlled the criteria of AML
CR1 having received an alloSCT with a RIC regimen. The
median age was 34 years (range: 2 e 63) and 60% were
males. The median time from diagnosis of AML to transplant
was 99 days (range: 41 e 504). 123 (89%) were HLA matched
related donors, 3 (2.1%) were MUD transplants and the rest
were HLA mismatched related donors. 70 (51%) received
chemotherapy consolidation prior to transplant, 61 (44%) did
not and data was not available in 7 (5%). 68% of those that
received consolidation received intermediate or low dose
cytosine based regimens. Fludarabine with melphalan
(140mg/m2) (128[93%]) was the most commonly used
regimen. All patients received a PBSC graft with a median
CD34 cell dose of 9.1x106/kg (range: 1.3 e 43). With the
exception of one, all patients engrafted (97% of these ach-
ieved complete chimerism at one month post transplant).
The median time to ANC >500/mm3 was 13 days (range: 7 e
22) and platelet count of >20,000/mm3 was 15 days (range:
0-33). Acute GVHD Grade 2-4 was seen in 29% and of patients
evaluated 62% had chronic GVHD, the majority of these being
limited (61%). The 100 day treatment relatedmortality (TRM)
was 7.5% and the one year TRMwas 25.6%. At amedian follow
up of 24 months the 5 year EFS and OS was 64.05.07 and
71.14.0 respectively. The 5 year cumulative incidence of
relapse was 21.8%. The baseline characteristics as mentioned
above were not signiﬁcantly different between the group
that received consolidation and the group that did not. The
use of consolidation therapy prior to alloSCT did not have a
signiﬁcant impact on EFS or OS.
On a multivariate analysis (after adjusting for those sig-
niﬁcant on univariate analysis and for conventional risk
factors) only CMV reactivation (RR 2.0; 95% CI 1.03-3.87;
P-value 0.042) and fungal infection (RR 7.1; 95% CI 3.154-
16.12; P-value 0.000) had a signiﬁcant adverse impact.
The mean costs of induction chemotherapy for these
patients was US$ 92393596 (n¼74) and for alloSCT it
was 1813813826 (n¼118; costing up to 1 year post
transplant). Induction chemotherapy followed by HLA
matched RIC alloSCT is likely to be the most cost effective
and affordable treatment option for young adults with
AML in CR1 in India. With an average gross net income in
India of US$3500/year the limitation still remains the cost
of treatment and number of centers that can offer this
therapy.
